ClinicalTrials.gg
CompletedNCT07185321Updated Jun 16, 2026

A Phase 1 Study of Mosliciguat in Healthy, Adult Males

A Phase 1 interventional study of Mosliciguat and 14C mosliciguat in Healthy Volunteer, sponsored by Pulmovant, Inc.. Completed at 1 site in United States. Open to male participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-16.

Sponsored by Pulmovant, Inc. · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Jun 2025, 1 year 4 months ago, and no results have been posted to the registry.
  • Registered 3 months after the study started (first participant enrolled Jun 2025, registered Sep 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Non-randomized
Ages
18 Years to 50 Years
Sex
Male
01

Study summary

This is a single-center, Phase 1, open-label, 3-period, fixed-sequence study to investigate the bioavailability, absorption, metabolism, excretion and the safety of mosliciguat administered to healthy male adults.

02

Conditions studied

  • Healthy Volunteer
03

In context

Lead sponsor

Pulmovant, Inc. is the lead sponsor of 4 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants willing and able to provide .
  • Considered to be in good health by the Investigator, as determined by medical history, physical examination, vital sign measurements, 12 lead (ECG), and laboratory test results.

Exclusion criteria

Exclusion Criteria:

  • History or presence of any condition (e.g., chronic diarrhea, urinary incontinence), or prior surgery (e.g., gastric bypass) that, in the opinion of the Investigator, poses a significant risk to participant safety and/or achievement of study objectives
  • History or presence of , moderate or persistent asthma, other chronic lung disease, or chronic respiratory condition within the last 5 years
  • Acute or recent respiratory infection symptoms not resolved at least 3 days prior to Period 1 check-in.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    Mosliciguat (RVT-2301)

    Mosliciguat administered daily via dry powder inhaler.

    Drug: Mosliciguat · Device: Dry Powder Inhaler

  • Experimental
    14C mosliciguat

    Administered orally and via IV

    Drug: 14C mosliciguat

Interventions

  • Dose level for inhalation

  • Drug14C mosliciguat

    Dose level

  • DeviceDry Powder Inhaler

    Dry powder inhaler for mosliciguat

06

What researchers measure

Primary outcomes

  1. Determine the absolute bioavailability (ABA) of mosliciguat following administration of a single inhaled dose of mosliciguat followed by an IV microtracer dose of [14C]-mosliciguat in healthy adult males

    Absolute bioavailability of inhaled mosliciguat

    Time frame: Baseline, Day 7

  2. Area under the concentration-time curve (AUC) for mosliciguat

    Time frame: Baseline, Day 7

  3. Assess the mass balance (i.e., cumulative excretion in urine and feces compared to the administered amount of radioactive isotope) of [14C] following a single oral dose of mosliciguat solution

    Urine and fecal recovery of total \[14C\] radioactivity, \[14C\]-mosliciguat

    Time frame: Baseline, Day 28

  4. Maximum observed concentration (Cmax)

    Time frame: Baseline, Day 7

Secondary outcomes

  1. Evaluate the incidence of Treatment-Emergent Adverse Events (safety and tolerability of mosliciguat)

    Incidence, nature, and severity of participant TEAEs, SAEs, and AEs

    Time frame: Baseline, Day 44

07

Study locations

1 site
  • Pharmaron
    Baltimore, Maryland 21201, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2025 to primary completion in Jun 2025, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2025
First posted
Sep 22, 2025
StartActual
Jun 10, 2025
Primary completionActual
Jun 30, 2025
CompletionActual
Jul 13, 2025
Last update
Jun 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07185321
Lead sponsor
Pulmovant, Inc.
Responsible party
Sponsor
First posted
Sep 22, 2025
Start date
Jun 10, 2025
Primary completion
Jun 30, 2025
Completion
Jul 13, 2025
Last update
Jun 16, 2026

Study contacts

Ubaldo Martin
study director · Pulmovant, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mosliciguat

Start the discussion